Adhera Therapeutics 10K 2022 Annual report | ATRX Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abnormal, acknowledgment, addressing, adipose, adult, adulthood, Africa, agonist, aimed, akinesia, Alberta, alleviate, amantadine, ameliorate, antagonist, antiviral, anxiety, API, armamentarium, attenuation, Australia, automated, bear, beta, blotchy, blurred, bradykinesia, brain, Brazil, Britain, Buteau, carbidopa, catecholamine, cell, China, chorea, clozapine, collateral, COMT, Comtan, contest, context, counteract, CRO, cure, DAT, DBS, debilitating, degradation, delisted, delisting, dialogue, diet, disappointing, disorder, dollar, DOPA, dopamine, dopaminergic, downgrade, downstream, duodenum, Duodopa, dyskinesia, dysregulation, dystonia, Eastern, effectuation, embark, energy, enigmatic, entacapone, entirety, Eurasia, Europe, excessive, exempt, exemption, expiry, explain, explanatory, factor, fat, fatigue, Figure, flux, fold, formatted, France, freely, Frontage, function, gastric, genetic, Germany, glucose, glycemic, GPi, hand, healing, hematopoietic, hepatic, hereunder, Hong, immune, implanted, Importantly, impulse, inflammatory, influenza, infusion, injected, insomnia, instability, insult, intermittent, interna, involuntary, Ireland, isolated, Israel, iXBRL, Japan, Jean, Justice, ki, kinase, Kong, Korea, levodopa, LID, liver, living, Luxemburg, lyn, Maladi, mechanism, mediated, mentioned, mesocarb, metabolism, metformin, Mexico, mice, minimum, Monaco, motor, mouse, necessitated, neural, neurodegenerative, NMDA, nonalcoholic, norepinephrine, odd, onset, PA, pancreatic, par, parkinsonian, paving, Peak, perspective, PGT, physiologically, pivotal, play, poor, postural, potent, PPAR, PPD, pramipexole, precursor, preferential, prepay, preserve, proliferation, prophylactically, prostate, protein, protocol, psychotropic, pulsatile, pumped, quantity, quotation, rank, rat, ratio, Rationale, ready, receptor, redemption, remarkable, restore, resume, retroactively, reuptake, rigidity, robust, Ropinirole, Schema, sector, serotonin, SERT, Singapore, skin, South, split, Src, Stalevo, stimulate, stimulation, STN, striatal, strongly, subthalamic, sudden, suggested, suggesting, surgery, surgical, Switzerland, synaptic, Tasmar, Taxeme, testimony, text, theory, thirst, tissue, tolcapone, tolimidone, tone, tradeable, transactivation, transferase, transporter, tremor, tyrosine, uncommon, underway, underwriter, unqualified, verbal, view, vii, vision, VWAP, waived, wide, Zahed, Zealand, Zucker

Removed: account, accuracy, affiliate, assistance, began, beneficially, California, CEO, close, committed, consolidation, depressive, electronically, empowered, Furnished, GmbH, goodwill, hope, implied, influence, inherently, international, Internet, legislation, liposomal, methodology, NaN, negotiating, Novosom, operation, outbreak, partnering, person, practicable, pressure, prolonged, promulgated, qualifying, resell, room, separately, shareholder, step, Street, suffered, turn, uneconomical, unpredictable, Washington, website

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date:	March 31, 2023

By:	/s/ Zahed Subhan
Name:	Zahed Subhan
Title:	Chief Executive Officer (Principal Executive Officer)

Adhera Therapeutics (ATRX) 10-K2022 FY Annual report

Content analysis